Skip to content

Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)

Lilly's Emotional and Physical Symptoms of Depression Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00479726
Acronym
LEAPS
Enrollment
8000
Registered
2007-05-28
Start date
2004-08-31
Completion date
2005-01-31
Last updated
2007-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

To assess the effectiveness of duloxetine administered once daily in patients with Major Depressive Disorder in a practice based setting

Detailed description

To assess physical and emotional symptoms of depressed patients

Interventions

DRUGduloxetine hydrochloride

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Meet criteria for major depressive disorder according to the DSM-IV diagnostic criteria * Outpatients at least 18 years of age * Sign the informed consent * All females must test negative for a urine pregnancy test at visit 1. Females of child bearing potential must agree to utilize medically acceptable and reliable means of birth control * Have a level of understanding sufficient to communicate with the investigator and are able to complete all patient self-rated scales in the study

Exclusion criteria

* Are investigator site personnel directly affiliated with the study or immediate family * Are employed by Eli Lilly and Company * Have received treatment within the last 30 days or are currently enrolled in a study with a drug that has not received regulatory approval for any indication at time of study entry * Current substance dependence, excluding nicotine and caffeine * Treatment with a monoamine oxidase inhibitor within 14 days prior to visit 1 or potential need to use an MAOI within 5 days after discontinuation of study drug * Acute liver injury or severe (Child-Pugh Class C) cirrhosis

Design outcomes

Primary

MeasureTime frame
Clinical Global Impression of Severity
Somatic Symptom Inventory
Depressive Symptomatology-Self Report

Secondary

MeasureTime frame
Patient Global Impression of Improvement
Mood and Physical Symptoms in Depression
Quality of Life Enjoyment Satisfaction Questionnaire-Short form

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 8, 2026